Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 6/20 | 0.77 |
| ▸ | HTR2A | P28223 | 3/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | HTR2C | P28335 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | HTR1D | P28221 | 1/20 | 0.77 |
| ▸ | HTR1B | P28222 | 1/20 | 0.77 |
| ▸ | HTR7 | P34969 | 1/20 | 0.77 |
| ▸ | CTSK | P43235 | 1/20 | 0.77 |
| ▸ | HTR6 | P50406 | 1/20 | 0.77 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.77 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.74 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.67 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.67 |
| ▸ | MC1R | Q01726 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378418 | 0.98 | MPO (0.74) | MPOHTR2ACYP3A4HTR2CCYP1A2 | |
| SCHEMBL5991724 | 0.98 | MPO (0.74) | MPOHTR2ACYP3A4HTR2CCYP1A2 | |
| SCHEMBL2378528 | 0.98 | MPO (0.74) | MPOHTR2ACYP3A4HTR2CCYP1A2 | |
| SCHEMBL29532652 | 0.95 | MPO (0.79) | MPOHTR2ACYP3A4HTR2CCYP1A2 | |
| SCHEMBL735189 | 0.95 | MPO (0.79) | MPOHTR2ACYP3A4HTR2CCYP1A2 | |
| Hydrochloric Acid SCHEMBL21546034 | 0.93 | PMP22 (0.80) | MPOHTR2ACYP3A4HTR2CCYP1A2 | |
| SCHEMBL7004146 | 0.91 | HTR2A (0.71) | MPOHTR2ACYP3A4HTR2CCYP1A2 | |
| SCHEMBL7889427 | 0.89 | HTR2A (0.69) | MPOHTR2ACYP3A4HTR2CCYP1A2 | |
| SCHEMBL7001306 | 0.89 | HTR2A (0.69) | MPOHTR2ACYP3A4HTR2CCYP1A2 | |
| SCHEMBL7004071 | 0.89 | HTR2A (0.69) | MPOHTR2ACYP3A4HTR2CCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1229082-A | Amine compound and its acid addition salt | ROUSSEL UCLAF (FR) | 1999-09-22 | — | — | CN | claimed |
| EP-0680967-B1 | Erythromycin derivatives, their process of preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (FR) | 1998-10-14 | — | — | EP | claimed |
| CN-1151746-A | Novel erythromycin derivatives, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1997-06-11 | — | — | CN | claimed |
| CN-109311876-A | heteroaryl estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2019-02-05 | — | — | CN | disclosed |
| EP-2722333-A1 | Spiro-indole derivatives for the treatment of parasitic diseases. | Novartis AG (CH) | 2014-04-23 | — | — | EP | disclosed |
| EP-2285808-B1 | SPIRO-INDOLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| CN-102015711-B | Spiro-indole derivatives for the treatment of parasitic diseases | NOVARTIS AG | 2013-05-01 | — | — | CN | disclosed |
| US-8399453-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-03-19 | — | — | US | disclosed |
| US-8399453-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-03-19 | — | — | US | disclosed |
| US-8399453-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-03-19 | — | — | US | disclosed |
| US-20110275613-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-10 | — | — | US | disclosed |
| US-4824852-A | Substituted indole compounds which have useful effects on the central nervous system | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-04-25 | — | — | US | disclosed |
| US-4740602-A | Indole derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-04-26 | — | — | US | disclosed |
| EP-0121716-B1 | INDOLE DERIVATIVES | MERCK PATENT GmbH (DE) | 1987-12-09 | — | — | EP | disclosed |
| EP-0206225-A2 | Indole derivatives | MERCK PATENT GmbH (DE) | 1986-12-30 | — | — | EP | disclosed |
| EP-0121716-A1 | Indole derivatives | MERCK PATENT GmbH (DE) | 1984-10-17 | — | — | EP | disclosed |
| EP-0114603-A1 | Indole derivatives | MERCK PATENT GmbH (DE) | 1984-08-01 | — | — | EP | disclosed |
| EP-0007399-B1 | INDOLYLALKYL AMINES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCESS FOR THEIR MANUFACTURE | MERCK PATENT GmbH (DE) | 1982-01-20 | — | — | EP | disclosed |
| US-4251538-A | Indolealkylamines and processes for their preparation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1981-02-17 | — | — | US | disclosed |
| EP-0007399-A1 | Indolylalkyl amines, pharmaceutical preparations containing them and process for their manufacture | MERCK PATENT GmbH (DE) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275613-A1 | ORGANIC COMPOUNDS | OTC, PC, OAT | MPO 97/4885HTR2A 4625/4885CYP3A4 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.